Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma.

An improved liquid chromatographic tandem mass spectrometric method for the determination of glimepiride in human plasma has been developed and fully validated. The article describes in detail the bioanalytical procedure and summarizes the validation results obtained. The samples were extracted using liquid--liquid extraction with a mixture of 1-chlorobutane-isopropanol-ethyl acetate (88:2:10, v/v/v). The chromatographic separation was performed on a reversed-phase Hypersil ODScolumn (250 x 4.6 mm i.d.; 5 microm particle size) using a mobile phase consisting of formic acid 0.05 M-acetonitrile (28:72, v/v), pumped at a flow rate of 0.3 ml min(-1) heated to 25 degrees C. The analytes were detected using an API 3000 triple quadrupole mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode. Tandem mass spectrometric detection enabled the quantitation of glimepiride down to 0.50 ng mL(-1). Calibration graphs were linear (r better than 0.998, n=1), in concentration range 0.50--1000 ng mL(-1), and the intra- and inter- day RSD values were less than 10.37 and 11.55% for glimepiride. The method was successfully applied to a kinetic study in order to assess the main pharmacokinetic parameters of glimepiride.

[1]  J. Balfour,et al.  Glimepiride , 1998, Drugs.

[2]  I. Salem,et al.  Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  W. Smyth Electrospray ionisation mass spectrometric behaviour of selected drugs and their metabolites , 2003 .

[4]  F. Peters,et al.  Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[6]  P. Neuvonen,et al.  Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride , 2001, Clinical pharmacology and therapeutics.

[7]  S. Altınöz,et al.  Analysis of glimepiride by using derivative UV spectrophotometric method. , 2001, Journal of pharmaceutical and biomedical analysis.

[8]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[9]  A. J. Bowen,et al.  Short-Term Comparison of Once- versus Twice-Daily Administration of Glimepiride in Patients with Non-Insulin-Dependent Diabetes Mellitus , 1997, The Annals of pharmacotherapy.

[10]  R. Rosskamp,et al.  Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[11]  N. York,et al.  Characterization of the Molecular Mode of Action of the Sulfonylurea, Glimepiride, at β-Cells , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[12]  E. Draeger Clinical profile of glimepiride. , 1995, Diabetes research and clinical practice.

[13]  W. Waldhäusl,et al.  DOSE LINEARITY ASSESSMENT OF GLIMEPIRIDE (AMARYL®) TABLETS IN HEALTHY VOLUNTEERS , 1994, Drug metabolism and drug interactions.

[14]  W. Waldhäusl,et al.  ABSOLUTE BIOAVAILABILITY OF GLIMEPIRIDE (AMARYL®) AFTER ORAL ADMINISTRATION , 1994, Drug metabolism and drug interactions.

[15]  K. Ratheiser,et al.  Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. , 1993, Arzneimittel-Forschung.

[16]  K. Lehr,et al.  Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. , 1990, Journal of chromatography.

[17]  K. Geisen Special pharmacology of the new sulfonylurea glimepiride. , 1988, Arzneimittel-Forschung.

[18]  J. A. Scarlett,et al.  The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects , 1984, Diabetes.